TD Cowen analyst Shaul Eyal increased the price target on Fortinet stock (NASDAQ:FTNT) to $135 from the previous target of $120, while maintaining a Buy rating on the shares. The adjustment follows ...

Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target The firm cited ...

In a report released yesterday, Troy Jensen from Cantor Fitzgerald reiterated a Buy rating on Kornit Digital (KRNT – Research Report), with a ...

Cantor Fitzgerald reaffirmed its Overweight rating and $118.00 price target for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company specializing in rare diseases. Currently ...

Cantor Fitzgerald analyst C. Canfield expects that the company will earn ($1.10) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $30.00 target price on the ...

Fortinet, Inc. (NASDAQ:FTNT – Free Report) – Stock analysts at Cantor Fitzgerald lowered their ... from $88.00 to $100.00 and gave the company a “market perform” rating in a report on ...

Cantor Fitzgerald came out and expressed concerns around the Magnificent Seven group, saying the stocks are “vulnerable,” suggesting that there could be a shift in fund flows towards different ...

The current valuation of ORIC Pharmaceuticals, according to Cantor Fitzgerald, does not fully account for its prostate cancer treatment potential. The analyst believes that the company's lung ...

As such, the insights provided by Cantor Fitzgerald analysts offer a glimpse into the company's strategic maneuvers in the face of industry challenges and opportunities. In other recent news ...

Cantor Fitzgerald raised concerns about the Magnificent Seven stocks, suggesting they may be at risk of losing investor interest as fund flows shift to other sectors. Revenue projections for 2025 are ...